ERBB2 and cardiotoxicity: However, it’s worth noting that the administration of PEG-LD 50 mg/m2 plus trastuzumab every 4 weeks for six cycles in patients with HER2-positive metastatic breast cancer resulted in the development of grade 1 cardiotoxicity in three patients (10%), without any symptomatic CHF27.